MDNA Life Sciences Inc. (MDLS)

MDNA Life Sciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 3.60M
Net Income (ttm) -3.79M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About MDLS

MDNA Life Sciences is a life sciences company focused on the development of liquid biopsy tests based on the mitochondrial genome. We have discovered novel biomarkers and designed laboratory assays, which we refer to as our Mitomic Technology, that are intended to use mitochondrial DNA to detect cancer earlier, more accurately, and less invasively than traditional methods. Though we have no commercially available FDA or foreign regulator approved products, we have licensed our intellectual property related to the Mitomic prostate cancer biomark... [Read more...]

Industry Health Care
Founded 2002
CEO Christopher C. Mitton
Employees 15
Stock Exchange NASDAQ
Ticker Symbol MDLS
Full Company Profile

Financial Performance

In 2020, MDLS's revenue was $106,009, a decrease of -97.06% compared to the previous year's $3.60 million. Losses were -$4.57 million, 52.2% more than in 2021.

Financial Statements

News

US IPO Weekly Recap: August Kicks off with a 2 IPO week

Two deals priced this week, but only one met the criteria to be included in our 2022 IPO stats. Four new filings, including two offering units, also trickled into the pipeline.

MDNA Life Sciences IPO Registration Document (S-1)

MDNA Life Sciences has filed to go public with an IPO on the NASDAQ.